Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
LaunchAudioCure Pharma Achieves Milestone in Enrollment for AC102 Study Aimed at Treating Sudden Hearing Loss
Nov 26, 2024
BerlinBiotechnologyHealth CareMedical
Product Description
AudioCure Pharma has enrolled more than 50% of planned patients in its Phase 2 clinical trial for the new compound AC102, which targets sudden hearing loss. This milestone highlights the need for effective treatments and the potential of AC102 as a promising alternative to current therapies.
Company Information
Company
AudioCure Pharma
Location
Berlin, Berlin, Germany
About
AudioCure Pharma is a Berlin-based start-up focused on developing innovative treatments for sudden hearing loss. The company is currently conducting a Phase 2 clinical trial to test the efficacy of its new compound, AC102. This compound aims to address the unmet medical needs associated with sudden hearing loss, an area characterized by a lack of effective therapies. AudioCure Pharma aspires to achieve a paradigm shift in treatment options for this condition.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment AudioCure Pharma ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.